Synagis Market Growth Through 2030 Creates New Strategic Opportunities
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Synagis Market Revenue Growth Supported By A CAGR Of % Through 2030
Growth during the historical period was driven by a rising number of RSV infections affecting infants, heightened awareness around preventive monoclonal antibody treatments, the expansion of neonatal intensive care units, the presence of reimbursement policies for RSV prophylaxis, and the regulatory clearance of pediatric biologic drugs.
The expansion anticipated during the forecast period is driven by greater funding for novel RSV prevention treatments, a heightened emphasis on long-acting monoclonal antibodies, the scaling up of biologic production capabilities, rising spending on children’s healthcare, and the growing uptake of precision immunotherapy methods. Key developments shaping this period encompass the broader use of monoclonal antibody-based RSV prevention, an increased focus on prophylactic pediatric immunotherapies, the growth of cold-chain reliant biologic delivery systems, a stronger priority on protecting high-risk infants, and enhancements in the scalable manufacturing of biologics.
Download A Free Sample Report For Comprehensive Market Insights:
Synagis Market Industry Drivers: What Is Driving Revenue Growth?
The synagis market is anticipated to experience growth driven by the rising incidence of chronic respiratory conditions. These conditions, which are long-term ailments affecting the lungs and airways and causing persistent breathing difficulties, are becoming more common. Their increased prevalence is linked to various influences such as the aging population, lifestyle choices like smoking, genetic predispositions, occupational exposures, and environmental pollution. Synagis, also known as palivizumab, is used to prevent severe respiratory syncytial virus (RSV) infections in high-risk infants and children, thereby helping to reduce complications and exacerbations for those already dealing with chronic respiratory issues. A report from the World Health Organization (WHO) and the European Respiratory Society, as noted in June 2025 by the Switzerland-based UN agency, indicated that chronic respiratory diseases impact over 80 million individuals, with many more cases remaining undiagnosed. This growing prevalence of chronic respiratory conditions is therefore a key factor fueling the expansion of the synagis market.
The synagis market is being significantly propelled forward by the observed increase in healthcare spending. Healthcare expenditure encompasses all financial resources allocated to the delivery of health services, encompassing medical treatments, hospital stays, medications, and preventive efforts. Several factors contribute to this rise in spending, including a growing elderly population, a higher incidence of chronic diseases, public health emergencies, and an escalating demand for various services. This increase in financial resources is paving the way for greater investment in preventive therapies for vulnerable populations, such as high-risk infants and young children. As healthcare budgets expand, a larger portion of funding is being directed towards medications like synagis, which are used to prevent severe respiratory illnesses. Data from the Office for National Statistics, a UK government department, highlighted in May 2024 that total healthcare expenditure experienced a 5.6% nominal increase between 2022 and 2023, a significant contrast to the 0.9% growth seen in 2022. This upward trend in healthcare expenditure is thus a major driver behind the growth of the synagis market.
Synagis Market Segment Outlook: Which Categories Are Expanding The Fastest?
The synagis market covered in this report is segmented –
1) By Clinical Indication: Respiratory Syncytial Virus (RSV) Prophylaxis, Premature Infants With Bronchopulmonary Dysplasia (BPD), Congenital Heart Disease (CHD), Immunocompromised Infants And Children
2) By Formulation: 50 Milligrams (mg)/0.5 Milliliters (mL), 100 Milligrams (mg)/1 Milliliters (mL)
3) By Distribution Channel: Wholesale Distributors, Online Retailers
4) By End-User: Pediatric, Adults
#Synagis Market Growth Trends: What Is Influencing The Future Outlook?
Key industry players in the Synagis market are actively pursuing drug approvals to deliver preventive treatments for respiratory syncytial virus (RSV), thereby tackling a critical unmet medical need. Drug approval involves a regulatory process where authorities assess a medication’s safety, effectiveness, and quality through clinical trial evidence prior to granting authorization for commercial use. For example, in September 2023, AstraZeneca Pharma India Ltd., a biopharmaceutical firm based in India, received approval from the Central Drugs Standard Control Organisation (CDSCO) to market palivizumab, a preventive approach for RSV. This injectable product is supplied as palivizumab 100 mg/ml in single-dose vials containing 50 mg/0.5 ml and 100 mg/ml formulations, designed for intramuscular delivery. Palivizumab is recommended for infants born at or before 35 weeks of gestation, children undergoing treatment for bronchopulmonary dysplasia (BPD), and those with hemodynamically significant congenital heart disease (CHD). This regulatory endorsement marks the first RSV preventive therapy to be made accessible in India.
Synagis Market Key Companies And Competitive Benchmarking
Major companies operating in the synagis market are Swedish Orphan Biovitrum AB
Access The Complete Synagis Market Report:
Synagis Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the synagis market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the synagis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
